161 related articles for article (PubMed ID: 35075163)
1. Impact of hemolysis on multi-OMIC pancreatic biomarker discovery to derisk biomarker development in precision medicine studies.
Searfoss R; Shah P; Ofori-Mensa K; Bussberg V; Tolstikov V; Greenwood B; Li H; Richardson K; Miller GM; DeCicco C; Granger E; Rodrigues LO; Grund EM; Moser AJ; Sarangarajan R; Narain NR; Kiebish MA
Sci Rep; 2022 Jan; 12(1):1186. PubMed ID: 35075163
[TBL] [Abstract][Full Text] [Related]
2. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.
Pan S; Chen R; Crispin DA; May D; Stevens T; McIntosh MW; Bronner MP; Ziogas A; Anton-Culver H; Brentnall TA
J Proteome Res; 2011 May; 10(5):2359-76. PubMed ID: 21443201
[TBL] [Abstract][Full Text] [Related]
3. Direct Assessment of Plasma/Serum Sample Quality for Proteomics Biomarker Investigation.
Greco V; Piras C; Pieroni L; Urbani A
Methods Mol Biol; 2017; 1619():3-21. PubMed ID: 28674873
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
Luo X; Liu J; Wang H; Lu H
Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
[TBL] [Abstract][Full Text] [Related]
5. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
6. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
7. Multi-Omic Admission-Based Prognostic Biomarkers Identified by Machine Learning Algorithms Predict Patient Recovery and 30-Day Survival in Trauma Patients.
Abdelhamid SS; Scioscia J; Vodovotz Y; Wu J; Rosengart A; Sung E; Rahman S; Voinchet R; Bonaroti J; Li S; Darby JL; Kar UK; Neal MD; Sperry J; Das J; Billiar TR
Metabolites; 2022 Aug; 12(9):. PubMed ID: 36144179
[TBL] [Abstract][Full Text] [Related]
8. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.
Pan S; Chen R; Brand RE; Hawley S; Tamura Y; Gafken PR; Milless BP; Goodlett DR; Rush J; Brentnall TA
J Proteome Res; 2012 Mar; 11(3):1937-48. PubMed ID: 22316387
[TBL] [Abstract][Full Text] [Related]
9. Proteomics as a systems approach to pancreatitis.
Williams JA
Pancreas; 2013 Aug; 42(6):905-11. PubMed ID: 23851428
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.
Saraswat M; Joenväärä S; Seppänen H; Mustonen H; Haglund C; Renkonen R
Cancer Med; 2017 Jul; 6(7):1738-1751. PubMed ID: 28573829
[TBL] [Abstract][Full Text] [Related]
11. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery.
Zhou C; Simpson KL; Lancashire LJ; Walker MJ; Dawson MJ; Unwin RD; Rembielak A; Price P; West C; Dive C; Whetton AD
J Proteome Res; 2012 Apr; 11(4):2103-13. PubMed ID: 22338609
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.
Parker CE; Borchers CH
Mol Oncol; 2014 Jun; 8(4):840-58. PubMed ID: 24713096
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
15. Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry.
Chou CY; Chang CT; Chen CJ
Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1():e8580. PubMed ID: 31502717
[TBL] [Abstract][Full Text] [Related]
16. Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases.
Yang J; Roy R; Jedinak A; Moses MA
Cancer J; 2015; 21(4):327-36. PubMed ID: 26222086
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Hemolysis on Cell-Free microRNA Biomarkers.
Kirschner MB; Edelman JJ; Kao SC; Vallely MP; van Zandwijk N; Reid G
Front Genet; 2013; 4():94. PubMed ID: 23745127
[TBL] [Abstract][Full Text] [Related]
18. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.
Titz B; Gadaleta RM; Lo Sasso G; Elamin A; Ekroos K; Ivanov NV; Peitsch MC; Hoeng J
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223557
[TBL] [Abstract][Full Text] [Related]
19. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.
Stepczynska A; Schanstra JP; Mischak H
Bioanalysis; 2016; 8(5):439-55. PubMed ID: 26891752
[TBL] [Abstract][Full Text] [Related]
20. From bedside to bench-practical considerations to avoid pre-analytical pitfalls and assess sample quality for high-resolution metabolomics and lipidomics analyses of body fluids.
Lehmann R
Anal Bioanal Chem; 2021 Sep; 413(22):5567-5585. PubMed ID: 34159398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
